Skip to main content
PMC home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1994 Feb;160(2):173–176.

Acquired hemophilia in a patient with myeloma.

L S Loftus 1, W N Arnold 1
PMCID: PMC1022331  PMID: 8160473

Full text

PDF
174

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brettler D. B., Forsberg A. D., Levine P. H., Aledort L. M., Hilgartner M. W., Kasper C. K., Lusher J. M., McMillan C., Roberts H. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med. 1989 Jun;149(6):1381–1385. [PubMed] [Google Scholar]
  2. Castaldi P. A., Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood. 1970 Mar;35(3):370–376. [PubMed] [Google Scholar]
  3. Fulcher C. A. Immunochemistry of factor VIII:C inhibitor antibodies. Am J Med. 1991 Nov 4;91(5A):6S–8S. doi: 10.1016/s0002-9343(91)80140-h. [DOI] [PubMed] [Google Scholar]
  4. Glueck H. I., Coots M. C., Benson M., Dwulet F. E., Hurtubise P. E. A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization. J Lab Clin Med. 1989 Mar;113(3):269–277. [PubMed] [Google Scholar]
  5. Glueck H. I., Hong R. A circulating anticoagulant in gamma-1A-multiple myeloma: its modification by penicillin. J Clin Invest. 1965 Nov;44(11):1866–1881. doi: 10.1172/JCI105294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Green D. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med. 1991 Nov 4;91(5A):14S–19S. doi: 10.1016/s0002-9343(91)80142-9. [DOI] [PubMed] [Google Scholar]
  7. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981 Jun 30;45(3):200–203. [PubMed] [Google Scholar]
  8. Green D., Tuite G. F., Jr Declining platelet counts and platelet aggregation during porcine VIII:C infusions. Am J Med. 1989 Feb;86(2):222–224. doi: 10.1016/0002-9343(89)90274-x. [DOI] [PubMed] [Google Scholar]
  9. Hultin M. B. Acquired inhibitors in malignant and nonmalignant disease states. Am J Med. 1991 Nov 4;91(5A):9S–13S. doi: 10.1016/s0002-9343(91)80141-8. [DOI] [PubMed] [Google Scholar]
  10. Kelsey P. R., Leyland M. J. Acquired inhibitor to human factor VIII associated with paraproteinaemia and subsequent development of chronic lymphatic leukaemia. Br Med J (Clin Res Ed) 1982 Jul 17;285(6336):174–175. doi: 10.1136/bmj.285.6336.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kernoff P. B. Rationale and evolution of therapy with porcine factor VIII:C. Am J Med. 1991 Nov 4;91(5A):20S–22S. doi: 10.1016/s0002-9343(91)80143-a. [DOI] [PubMed] [Google Scholar]
  12. Kessler C. M. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med. 1991 Nov 4;91(5A):1S–5S. doi: 10.1016/s0002-9343(91)80139-d. [DOI] [PubMed] [Google Scholar]
  13. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin Hematol. 1973 Apr;10(2):125–133. [PubMed] [Google Scholar]
  14. Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis. 1974;3(2):65–93. doi: 10.1159/000214043. [DOI] [PubMed] [Google Scholar]
  15. Lusher J. M. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition. Am J Med. 1991 Nov 4;91(5A):30S–34S. doi: 10.1016/s0002-9343(91)80146-d. [DOI] [PubMed] [Google Scholar]
  16. Morrison A. E., Ludlam C. A., Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood. 1993 Mar 15;81(6):1513–1520. [PubMed] [Google Scholar]
  17. Morrison A. E., Ludlam C. A. The use of porcine factor VIII in the treatment of patients with acquired hemophilia: the United Kingdom experience. Am J Med. 1991 Nov 4;91(5A):23S–26S. doi: 10.1016/s0002-9343(91)80144-b. [DOI] [PubMed] [Google Scholar]
  18. Muhm M., Grois N., Kier P., Stümpflen A., Kyrle P., Pabinger I., Bettelheim P., Hinterberger W., Lechner K. 1-Deamino-8-D-arginine vasopressin in the treatment of non-haemophilic patients with acquired factor VIII inhibitor. Haemostasis. 1990;20(1):15–20. doi: 10.1159/000216100. [DOI] [PubMed] [Google Scholar]
  19. Niléhn J. E., Nilsson I. M. Coagulation studies in different types of myeloma. Acta Med Scand Suppl. 1966;445:194–199. doi: 10.1111/j.0954-6820.1966.tb02360.x. [DOI] [PubMed] [Google Scholar]
  20. Perkins H. A., MacKenzie M. R., Fudenberg H. H. Hemostatic defects in dysproteinemias. Blood. 1970 May;35(5):695–707. [PubMed] [Google Scholar]
  21. Sultan Y., Kazatchkine M. D., Nydegger U., Rossi F., Dietrich G., Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. Am J Med. 1991 Nov 4;91(5A):35S–39S. doi: 10.1016/s0002-9343(91)80147-e. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES